A Phase II/III, Multicentre, 8-week Run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, with a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 Mg Basimglurant in Patients with Pain Associated with Trigeminal Neuralgia with Suboptimal Response to Their Current Anti-pain Therapy.
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Basimglurant (Primary)
- Indications Facial pain; Pain; Trigeminal neuralgia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LibraTN
- Sponsors Noema Pharma
- 26 Mar 2024 Planned End Date changed from 30 Aug 2024 to 31 Jan 2026.
- 26 Mar 2024 Planned primary completion date changed from 30 Apr 2024 to 31 Jan 2025.
- 28 Feb 2023 Planned End Date changed from 20 May 2024 to 30 Aug 2024.